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Despite the advent of a raft of novel drug
strategies in MS which reduce relapse rate,
the problem of trying to slow or stop disease
progression remains. This applies both to
primary (PPMS) and secondary progressive
(SPMS) disease states, the latter typically
occurring 10-15 years after disease onset. In
this context, novel strategies for trial design
are required that allow a number of putative
compounds to be tested, dropping after a first
stage drugs which appear to have no
significant effect on disease progression,
whilst taking the promising compounds to the
next stage.
A comprehensive review of the available
literature was undertaken to inform the
simulations. This identified 1087 abstracts,
and also 9 clinical databases (including about
1500 patients) were obtained, from UK MS
centres/SLC, and analyzed.
• This is the first time that adaptive seamless
designs (ASD) have been suggested,
developed and shown to be feasible for
secondary progressive MS.
• The ASD approach combines the
‘conventional’ phase II and III stages of a
clinical programme into a single study and
thus provides savings by requiring fewer
patients.
• ASD based on early outcomes performs well
provided we have a ‘biologically plausible’
outcome measure for treatment selection.
This concept differs from a ‘surrogate’ marker,
in that it only has to give some indication as to
whether the treatment is working or not, rather
than making predictions for treatment effects
on the long term clinical outcome.
• When information is available on two key
design options, the number of test treatments
and the likely treatment effect types, a
definitive statement giving optimal settings for
the design parameters of a future study can
be made.
MS-AD web pages: http://www.warwick.ac.uk/go/ms_adaptive
Figure 1. Recruitment and follow-up of
patients
An example trial design for 4 test treatments
and a control (placebo) group is shown in
Figure 2.
A simulation study was conducted to
investigate a range of potential options for the
trial design including when to carry out the
interim analysis and how to select treatments
at the interim analysis. These are virtual trials
based on realistic assumptions about the
distributions of the endpoints, effect sizes,
correlations etc, using information from
available data, literature review and expert
opinion. A set of modular functions (Fig. 3)
were developed in the R (www.r-project.org)
statistical programming environment to
implement the simulations.
Results
The curves (Fig. 4) show the power to
successfully detect a single effective
treatment from 4 test treatments plotted
against the total trial sample size (patients) for
a flexible selection rule and a conventional
(phase II and phase III) design. Many
thousands of plausible clinical scenarios were
tested, using a range of design options and
assumptions.
The focus of this work is the development of
methods for comparison of a number of
experimental treatments with a common
control in a single study with two distinct
stages. Patients will be recruited over 2 years
and followed up for 3 years (Fig. 1). At the
end of the first stage, after between 1 and 2
years, an interim analysis of data on an ‘early’
outcome measure will be used to select
treatments for stage 2. At the end of stage 2,
inference will be based on the ‘final’ outcome
measure for all patients recruited from both
stages.
Figure 2. Design for 4 treatments and a
control, with n1 patients in each group at stage
1 and n2 patients in each group at stage 2
Figure 3. Structure of R
functions for implementation
of ASD
Figure 4. Power curves
comparing ASD to a
conventional design
